CHI3L1 and neuromyelitis optica: Blocking this axis — pharmacologically or via astrocyte-specific RAGE deletion — attenuated demyelination, glial activation, and motor deficits, highlighting the CHI3L1-RAGE interaction as a promising therapeutic target and clarifying its role in NMO pathogenesis.